Advertisement
  • Genetic Testing Gaps

    Testing for hereditary mutations is increasingly recommended for people with cancer, but recommendations do not always translate into access to testing and appropriate counseling.

    by Kate Yandell

  • Understanding How Radiation Causes Cancer

    Researchers are investigating who is at greatest risk for radiation-induced cancers.

    by Kate Yandell

  • Making Connections at the AACR Annual Meeting 2021

    Attending a scientific conference as a patient advocate can be an exhausting, overwhelming and hugely rewarding experience.

    by Bradley Jones

  • Building COVID-19 Vaccine Confidence

    Experts discussed how the cancer community can share accurate information and increase confidence in COVID-19 vaccines, both among people with cancer and the general population.

    by Kevin McLaughlin

  • Chemobrain: It’s Not Your Imagination

    Scientists discussed the mechanisms of chemotherapy-related cognitive impairment at a session dedicated to symptom science at the AACR Annual Meeting 2021.

    by Marci A. Landsmann

  • Coverage of the AACR Annual Meeting 2021

    This year's AACR Annual Meeting features the latest advances in basic, translational and clinical cancer research. The more than 13,000 attendees at the virtual event represent more than 70 countries.

    by Kevin McLaughlin

  • Searching the Blood for Signs of Altered Immunity

    The immune systems of people with blood cancer respond differently to infection with the coronavirus than the immune systems of people without cancer or with solid tumors.

    by Kate Yandell

  • Physicians Underestimate Severity of Radiation Side Effects

    Breast cancer patients' symptoms after radiation therapy may go underrecognized, especially if these patients are Black or younger in age.

    by Marci A. Landsmann

  • Drug Dependence After Breast Surgery

    A study indicates that some breast cancer patients who receive mastectomy and reconstruction may be at risk of persistent drug use following surgery.

    by Marcus A. Banks

  • Targeted Therapy for Early-Stage Lung Cancer?

    A trial of the targeted therapy Tagrisso (osimertinib) for early-stage lung cancer finds that patients who take it go longer without having a cancer recurrence. Whether that should change clinical practice is under discussion.

    by Ashley P. Taylor

Advertisement